SCHEMBL5274756

SCHEMBL5274756

NC1(Cc2cc(C(F)(F)F)cc(C(F)(F)F)c2)CC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 2/20 0.47
MAOA P21397 1/20 0.45
MAOB P27338 1/20 0.45
TSHR P16473 1/20 0.41
CYP2D6 P10635 4/20 0.41
CYP3A4 P08684 3/20 0.41
CACNA1G O43497 1/20 0.40
CACNA1H O95180 1/20 0.40
CACNA1B Q00975 1/20 0.40
CACNA1C Q13936 1/20 0.40
TACR1 P25103 6/20 0.37
USP2 O75604 2/20 0.37
CYP2C19 P33261 2/20 0.37
CYP1A2 P05177 1/20 0.37
MEN1 O00255 1/20 0.37
TP53 P04637 1/20 0.37
KMT2A Q03164 1/20 0.37
HPGD P15428 1/20 0.36
SLC6A4 P31645 2/20 0.35
CYP2C9 P11712 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2473067 0.82 TAAR1 (0.54) IDO1MAOAMAOBTSHRSLC6A4
SCHEMBL1825520 0.80 MAOB (0.55) IDO1MAOAMAOBKMT2A
SCHEMBL15168718 0.73 TACR1 (0.41) IDO1TSHRCYP2D6CYP3A4TACR1
SCHEMBL5275909 0.73 HSD11B1 (0.43) IDO1TSHRCYP2D6CYP3A4TACR1
SCHEMBL1823510 0.72 MAOA (0.50) IDO1MAOAMAOBSLC6A4
SCHEMBL42797 0.69 IDO1 (0.58) IDO1MAOBCACNA1CTACR1
SCHEMBL5676540 0.68 TACR1 (0.36) IDO1TSHRCYP2D6CYP3A4TACR1
SCHEMBL1821778 0.68 MAOA (0.50) MAOAMAOBTSHRTACR1KMT2A
SCHEMBL5249761 0.68 IDO1 (0.56) IDO1TSHRCACNA1CTACR1
Hydrochloric Acid SCHEMBL2898331 0.67 IDO1 (0.59) IDO1MAOBCACNA1CTACR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1620403-B1 NOVEL 3,4-DISUBSTITUTED 1,2,3,6-TETRAHYDROPYRIDINE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2007-11-28 EP disclosed
US-20060235056-A1 Novel 3,4-disubstituted 1,2,3,6-tetrahydropyridine derivatives ACTELION PHARMACEUTICALS LTD. (CH) 2006-10-19 US disclosed
EP-1620403-A1 NOVEL 3,4-DISUBSTITUTED 1,2,3,6-TETRAHYDROPYRIDINE DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2006-02-01 EP disclosed
WO-2004096769-A1 NOVEL 3,4-DISUBSTITUTED 1,2,3,6-TETRAHYDROPYRIDINE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2004-11-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060235056-A1 Novel 3,4-disubstituted 1,2,3,6-tetrahydropyridine derivatives REN, ACE, ACE2 IDO1 1372/4885MAOA 1001/4885MAOB 1107/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.